北极狐（Vulpes lagopus）中Raboral V-RG®口服狂犬病疫苗的初步评估。
Preliminary evaluation of Raboral V-RG® oral rabies vaccine in Arctic foxes (Vulpes lagopus).
作者信息
Follmann Erich, Ritter Don, Swor Rhonda, Dunbar Mike, Hueffer Karsten
机构信息
Institute of Arctic Biology, Department of Biology and Wildlife, University of Alaska Fairbanks, 902 North Koyukuk Dr. Irving1 #311, Fairbanks, Alaska 99775, USA.
出版信息
J Wildl Dis. 2011 Oct;47(4):1032-5. doi: 10.7589/0090-3558-47.4.1032.
We tested the Raboral V-RG® recombinant oral rabies vaccine for its response in Arctic foxes (Vulpes lagopus), the reservoir of rabies virus in the circumpolar North. The vaccine, which is currently the only licensed oral rabies vaccine in the United States, induced a strong antibody response and protected foxes against a challenge of 500,000 mouse intracerebral lethal dose 50% of an Arctic rabies virus variant. However, one unvaccinated control fox survived challenge with rabies virus, either indicating a high resistance of Arctic foxes to rabies infection or a previous exposure that induced immunity. This preliminary study suggested that Raboral V-RG vaccine may be efficacious in Arctic foxes.
我们测试了Raboral V-RG®重组口服狂犬病疫苗在北极狐（Vulpes lagopus）中的反应，北极狐是环极北极地区狂犬病病毒的宿主。该疫苗是目前美国唯一获得许可的口服狂犬病疫苗，它诱导了强烈的抗体反应，并保护狐狸免受500,000个小鼠脑内致死剂量的北极狂犬病病毒变种的攻击。然而，一只未接种疫苗的对照狐狸在感染狂犬病病毒后存活下来，这要么表明北极狐对狂犬病感染具有高度抵抗力，要么表明它之前曾接触过病毒从而产生了免疫力。这项初步研究表明，Raboral V-RG疫苗可能对北极狐有效。
Zotero 插件